Breaking News

Nordion To Divest Targeted Therapies Business

May 23, 2013

BTG to acquire TheraSphere

Nordion, Inc. has entered into an agreement to divest its Targeted Therapies business to BTG plc, a specialist healthcare company based in London, for $200 million in cash. The transaction is expected to close by the end of June 2013.
BTG will acquire TheraSphere, a targeted liver cancer therapy, and Nordion has agreed to continue manufacturing TheraSphere under a Manufacturing and Support Agreement for three years, plus a two-year extension at BTG’s option. Approximately 40 Nordion employees are expected to join BTG.
“Nordion built TheraSphere into a valuable product over the past decade and has positioned it for future growth and development. Given BTG’s position as a leader in interventional medicine, we believe it is an ideal home for TheraSphere and the talented people that support it,” said Steve West, chief executive officer, Nordion. “We also believe this transaction provides value for our shareholders and leaves Nordion with a focused specialty isotopes business. We intend to continue our strategic review process which includes an assessment of potential uses for the cash proceeds from this sale.”
blog comments powered by Disqus
  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • The Search &  Rescue Mission for Data Integrity

    The Search & Rescue Mission for Data Integrity

    Mike Jovanis, Vice President of Vault QualityDocs, Veeva Systems||October 11, 2016
    Cloud technology is essential for success